C-APS

T:APS - APTOSE BIOSCIENCES INC. - https://aptose.com/

22:29:08 EST

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
APS - T	2.3	2.20	·	2.30	3.0	2.23			8.4	18	23	2.22 2.24 2.22	12.60 1.02	15:39:00	Jan 16	15 min RT 2¢
TSX - T	2.3	2.20	·	2.30	3.0	2.23			8.0	18	8	2.22 2.24 2.22	12.60 1.02	15:39:00		15 min
CSE ATS - P						2.22	-0.01	-0.4	0.1	0	2	2.22 2.22 2.22		12:33:27		15 min
CXD - D						2.23			0.2	0	8			Dec 24		15 min
MatchNOW - M						2.23			0.1	0	5			Sep 11/20		15 min

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
NOTE: Delayed ATS trade data is included - click System Status for more information

Hide ATS · Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · Company · Participants · 1yr Bulletins · Sedar · Historical · Options · Shorts · Portfolio

Recent Trades - Last 10 of 23

More trades...

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
15:39:00	T	2.23		1,000	1 Anonymous	13 Instinet	K
15:30:27	M	2.29	0.06	1	7 TD Sec	2 RBC	E
14:08:16	D	2.23		1	1 Anonymous	124 Questrade	E
12:33:27	P	2.22	-0.01	100	1 Anonymous	13 Instinet	K
12:33:27	T	2.22	-0.01	1,400	2 RBC	13 Instinet	K
12:33:27	T	2.22	-0.01	4,900	1 Anonymous	13 Instinet	K
12:33:27	T	2.23		400	80 National Bank	13 Instinet	K
12:33:27	M	2.23		60	1 Anonymous	13 Instinet	E
12:30:55	M	2.23		54	1 Anonymous	1 Anonymous	E
12:30:55	T	2.23		100	80 National Bank	1 Anonymous	K

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Price	Type	Headline
2026-01-16 19:49	C:APS	2.24	Miscellaneous270	Aptose Biosciences delisting review extended
2025-12-19 19:16	C:APS	2.08	News Release200	Aptose Biosciences to reschedule special meeting
2025-12-08 07:36	C:APS	2.31	News Release200	Aptose releases tuspetinib triple drug therapy data
2025-11-19 01:22	C:APS	2.24	News Release200	Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
2025-11-13 17:18	C:APS	1.94	SEDAR Interim Financial Statements812	SEDAR Interim Financial Statements
2025-11-13 17:18	C:APS	1.94	SEDAR Interim MD & A813	SEDAR Interim MD & A
2025-11-13 17:00	C:APS	1.94	News Release200	Aptose Reports Third Quarter 2025 Results
2025-11-03 09:00	C:APS	1.88	News Release200	Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
2025-10-16 07:30	C:APS	1.59	News Release200	Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
2025-09-22 17:01	C:APS	1.72	News Release200	Aptose enters $11.9M (U.S.) amended loan facility
2025-08-22 17:27	C:APS	1.58	News Release200	Aptose Biosciences appoints Ernst & Young auditor
2025-08-18 17:01	C:APS	1.85	News Release200	Aptose releases Tuspetinib early results for AML
2025-08-13 16:57	C:APS	1.72	SEDAR Interim Financial Statements812	SEDAR Interim Financial Statements
2025-08-13 16:57	C:APS	1.72	SEDAR Interim MD & A813	SEDAR Interim MD & A
2025-08-13 16:30	C:APS	1.72	News Release200	Aptose Reports Second Quarter 2025 Results
2025-08-06 16:30	C:APS	1.73	News Release200	Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
2025-08-01 16:29	C:APS	1.68	News Release200	Aptose Biosciences selects Ernst & Young as auditor
2025-07-15 19:59	C:APS	2.12	News Release200	Aptose receives advance of $2M (U.S.) from facility
2025-07-01 08:00	C:APS	1.15	News Release200	Aptose Upgraded to Trade on OTCQB Market
2025-06-30 19:55	C:APS	1.15	News Release200	Aptose Biosciences, Hanmi enter interest deferral deal

Date ET

Symbol

Price

Type

Headline

2026-01-16 19:49

C:APS

2.24

Miscellaneous

Aptose Biosciences delisting review extended

2025-12-19 19:16

C:APS